In vivo tolerance and kinetics of a novel ocular drug delivery device

2006 ◽  
Vol 116 (2) ◽  
pp. e47-e49 ◽  
Author(s):  
R.T. Pijls ◽  
H.H.L. Hanssen ◽  
R.M.M.A. Nuijts ◽  
G.W. Daube ◽  
L.H. Koole
Keyword(s):  
Drug Delivery ◽  
Ocular Drug Delivery ◽  
Delivery Device ◽  
Drug Delivery Device ◽  
Kinetics Of

An Implantable Device Design Concept for Ocular Drug Delivery

2012 ◽  
Author(s):  
Jae-Hwan Lee ◽  
Ramana M. Pidaparti
Keyword(s):  
Drug Delivery ◽  
Macular Degeneration ◽  
Ocular Drug Delivery ◽  
Eye Diseases ◽  
Age Related Macular Degeneration ◽  
Intravitreal Injections ◽  
Delivery Device ◽  
Drug Delivery Device ◽  
Age Related ◽  
Intraocular Hemorrhage

New drugs for curing eye diseases have been developing for a decade and are very unique for each eye diseases such as glaucoma, cataracts, and age-related macular degeneration (AMD). It is estimated that 1.6 million adults in the US over the age of 50 and above suffer from age-related macular degeneration and about 200,000 cases are diagnosed annually. Worldwide, about 500,000 cases are diagnosed annually [1]. Drugs currently utilized for AMD are delivered via repeated intravitreal injections of the drug into the eye. Risks of repeated intravitreal injections can include intraocular infections (endophthalmitis), intraocular hemorrhage, and retinal detachment. Also, reducing the frequency of dosing will clearly benefit the patient by reducing the need for risky intravitreal injections and improving the pharmacokinetics of the drug in the eye. The eye disease of posterior segment (Dry and Wet) has limits to deliver the drug to retina region using typical eye drop. The drug injection using a needle with syringe can deliver but it barely provide right amount of doses, or over doses that may cause more severe problem such as swelling, fatigue, and damaging photoreceptor molecules. Furthermore, most drugs run away in a month so that repeated injection is necessary. Developing an implantable drug delivery device will help reduce the costs and risks associated with frequent injections and facilitate delivering the drug in a controlled manner and in the required amounts, and improve therapeutic efficacy and safety of drugs. This study focuses on the design, simulation and development of the implantable ocular drug delivery device.

In Vitro–In Vivo Evaluation of an Oral Ghost Drug Delivery Device for the Delivery of Salmon Calcitonin

2018 ◽  
Vol 107 (6) ◽  
pp. 1605-1614 ◽  
Author(s):  
Angus R. Hibbins ◽  
Mershen Govender ◽  
Sunaina Indermun ◽  
Pradeep Kumar ◽  
Lisa C. du Toit ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Salmon Calcitonin ◽  
Delivery Device ◽  
In Vivo Evaluation ◽  
Drug Delivery Device

scholarly journals Soft implantable drug delivery device integrated wirelessly with wearable devices to treat fatal seizures

2021 ◽  
Vol 7 (1) ◽  
pp. eabd4639
Author(s):  
Hyunwoo Joo ◽  
Youngsik Lee ◽  
Jaemin Kim ◽  
Jeong-Suk Yoo ◽  
Seungwon Yoo ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Survival Rates ◽  
Animal Experiments ◽  
Wearable Devices ◽  
Delivery Device ◽  
Drug Delivery Device ◽  
Novel Treatment ◽  
Medical Emergencies

Personalized biomedical devices have enormous potential to solve clinical challenges in urgent medical situations. Despite this potential, a device for in situ treatment of fatal seizures using pharmaceutical methods has not been developed yet. Here, we present a novel treatment system for neurological medical emergencies, such as status epilepticus, a fatal epileptic condition that requires immediate treatment, using a soft implantable drug delivery device (SID). The SID is integrated wirelessly with wearable devices for monitoring electroencephalography signals and triggering subcutaneous drug release through wireless voltage induction. Because of the wireless integration, bulky rigid components such as sensors, batteries, and electronic circuits can be moved from the SID to wearables, and thus, the mechanical softness and miniaturization of the SID are achieved. The efficacy of the prompt treatment could be demonstrated with animal experiments in vivo, in which brain damages were reduced and survival rates were increased.

In Vivo Inflammatory and Wound Healing Effects of Gold Electrode Voltammetry for MEMS Micro-Reservoir Drug Delivery Device

2004 ◽  
Vol 51 (4) ◽  
pp. 627-635 ◽  
Author(s):  
G. Voskerician ◽  
R.S. Shawgo ◽  
P.A. Hiltner ◽  
J.M. Anderson ◽  
M.J. Cima ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Wound Healing ◽  
Gold Electrode ◽  
Delivery Device ◽  
Drug Delivery Device

Magnetically-actuated drug delivery device (MADDD) for minimally invasive treatment of prostate cancer: An in vivo animal pilot study

The Prostate ◽  
2017 ◽  
Vol 77 (13) ◽  
pp. 1356-1365 ◽  
Author(s):  
Werner J. Struss ◽  
Zheng Tan ◽  
Payam Zachkani ◽  
Igor Moskalev ◽  
John K. Jackson ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Drug Delivery ◽  
Pilot Study ◽  
Minimally Invasive ◽  
Minimally Invasive Treatment ◽  
Delivery Device ◽  
Invasive Treatment ◽  
Drug Delivery Device ◽  
Magnetically Actuated

An in-vivo evaluation of a MEMS drug delivery device using Kunming mice model

2015 ◽  
Vol 17 (1) ◽  
Author(s):  
Yaqian Liu ◽  
Peiyi Song ◽  
Jianwei Liu ◽  
Danny Jian Hang Tng ◽  
Rui Hu ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Mice Model ◽  
Delivery Device ◽  
In Vivo Evaluation ◽  
Drug Delivery Device
Sign in / Sign up

Export Citation Format

Share Document